Advantageous Activities All TRIB1 Addict Definitely Should Check

HCC, hepatocellular carcinoma; TRIB1 mOS, median overall survival; mPFS, median progression-free survival. Figure 2 Kaplan-Meier curves for survival for patients with HCC based on Child-Pugh score. (A) mOS for CP-A versus CP-B cirrhosis; (B) mPFS for CP-A versus CP-B cirrhosis. HCC, hepatocellular carcinoma; mOS, median overall survival; mPFS, median progression-free ... Dose Among 102 patients with dosing data available, mOS for patients starting sorafenib at a total of 400 mg/day (n=33) was 6.6 months (95% CI: 3.8-10.8) vs. those starting at 800 mg/day (n=69) was 12.8 months (95% CI: 7.8-15.9) (HR, 0.59; 95% CI: 0.36-0.97, P=0.04). The mPFS was 3.5 months for 400 mg/day (95% CI: 1.8-6.2) vs. 5.9 months (95% CI: 4.6-8.4) for 800 mg/day (HR, 0.66; 95% CI: 0.42-1.03; P=0.07). Among patients with CP-A cirrhosis, patients receiving 400 mg/day (n=12) had mOS of 15.8 vs. 12.8 months for 800 mg/day (n=43) CP-A patients (HR, 1.48; 95% CI: 0.65-3.39; P=0.35) (Figure 3A). The mPFS was 9.0 months for 400 mg/day vs. 5.9 months for 800 mg/day CP-A patients (HR, 1.23; 95% CI: 0.61-2.51; P=0.56) (Figure 3B). Among patients with CP-B, mOS was 5.0 months for 400 mg/day (n=21) vs. 11.2 months for 800 mg/day (n=25) (HR, 0.33; BTK inhibitor 95% CI: 0.16-0.70; P=0.002) (Figure 3C). The mPFS was 2.1 months for 400 mg/day vs. 5.6 months for 800 mg/day CP-B patients (HR, 0.41; 95% CI: 0.22-0.79; P=0.006) (Figure 3D). Figure 3 Kaplan-Meier curves for survival based on sorafenib dose in HCC patients with CP-A and CP-B cirrhosis. (A) mOS for HCC patients with CP-A cirrhosis given 400 vs. 800 mg sorafenib/day; (B) mPFS for HCC patients with CP-A cirrhosis given 400 vs. 800 mg ... CLIP score Among CP-A patients, the mOS based on CLIP score of 0-2 (n=51) was 14.0 vs. 7.9 months for CLIP score of 3+ (n=9) (HR, 1.68; 95% CI: 0.73-3.88; P=0.22), and the mPFS for CLIP score of 0-2 was 7.1 vs. 6.5 months for CLIP score of 3+ (HR, 1.40; 95% CI: 0.65-3.04; P=0.38). Among CP-B patients, the mOS based on CLIP score of 1-2 (n=20) was 8.5 vs. 5.9 months for CLIP score of 3+ (n=26) (HR, 1.12; 95% CI: 0.57-2.18; P=0.74), and the mPFS for CLIP score of 1-2 was 4.6 vs. 3.5 months for CLIP score of 3+ (HR, 1.62; 95% CI: 0.85-3.09; P=0.14). MK-2206 order Ethnicity The mOS for Hispanics (n=78) was 11.2 (95% CI: 7.2-18.4) vs.